CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
6 research outputs found
Detailed analysis of adenosine A2a receptor ( ADORA2A
Author
Innate Pharma
Lechner M
United States Food and Drug Administration. pembrolizumab (KEYTRUDA)
Publication venue
'Informa UK Limited'
Publication date
Field of study
No full text
Crossref
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
Author
Adebayo Ogunniyi
Alexander Drilon
+9 more
Brahmer JR
Goldberg SB
Meagan S Barbee
Mok T
Papadimitrakopoulou V
Patnaik A
Pembrolizumab (Keytruda®)
Rizvi NA
Thu Oanh Dang
Publication venue
'Informa UK Limited'
Publication date
Field of study
No full text
Crossref
Treatment patterns of malignant melanoma in the United States from 2011 to 2016: a retrospective cohort study
Author
Arondekar B
Avastin® (Bevacizumab
+14 more
BRAFTOVITM (encorafenib
COTELLIC® (cobimetinib)
David Cohan
KEYTRUDA® (pembrolizumab)
Leon Raskin
MEKINIST® (trametinib)
MEKTOVITM (binimetinib
Morganna Freeman
Omid Hamid
Opdivo® (nivolumab
Shweta Shah
TAFINLAR® (dabrafenib).
Yervoy® (ipilimumab
ZELBORAF® (vemurafenib
Publication venue
'Informa UK Limited'
Publication date
Field of study
No full text
Crossref
Intratumoral Immunotherapy—Update 2019
Author
Abou‐Alfa GK
Au GG
+16 more
Baines J
De Pace N
Diab A
Hecht JR
Igor Puzanov
Imlygic (talimogene laherparepvec)
Kasuya H
Keytruda (pembrolizumab)
Kimata H
Link BK
Liu H
Maker AV
Omid Hamid
Opdivo (nivolumab)
Rubina Ismail
Yervoy (ipilimumab)
Publication venue
'Alphamed Press'
Publication date
Field of study
No full text
Crossref
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE
Author
Aaron Hansen
Adnan Nagrial
+18 more
Andrea Iolanda Varga
Antoine Italiano
David Malka
Do‐Youn Oh
Filippo Braud
Hope S. Rugo
Hui Wang
Hyun Cheol Chung
Kazuhiko Nakagawa
Kevin G. Norwood
KEYTRUDA (pembrolizumab)
Lamarca A
Makoto Ueno
Robin K. Kelley
Sarina A. Piha‐Paul
Suba Krishnan
Toshihiko Doi
Willeke Ros
Publication venue
'Wiley'
Publication date
Field of study
No full text
Crossref
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
Author
A Bacic
A Jonas
+45 more
A Jonas
AS Chan
ASH Chan
ASH Chan
Avastin® (bevacizumab) Prescribing Information
B Besse
B Li
B Li
C Halstenson
C Qi
C Salvador
CG Azzoli
F. Schneller
G Cornelio
J. F. Marier
J. Kollmeier
J. Lowe
J. R. Trout
K Fraser
K Fraser
K. Gorden
Keytruda® (pembrolizumab) Prescribing Information
M. Beliveau
M. Gargano
M. L. Patchen
M. Thomas
MB Tamayo
MB Tamayo
N Bose
N Bose
N. Bose
P. Mattson
P. Sadjadian
PM Kidd
R Pirker
R. Walsh
RB Fulton
SM Leonardo
SM Leonardo
Tecentriq® (atezolizumab) Prescribing Information
TJ Lynch
TT Chen
W Zhong
WS Engel-Riedel
Z Zhou
Publication venue
'Springer Science and Business Media LLC'
Publication date
Field of study
No full text
Crossref